Covalon Technology Limited (COV)

[zenvesting]

In a third party in vitro simulated vascular insertion study designed to measure the levels of particulate, Covalon’s Centaur™ coating resulted in statistically significantly lower levels for all particulate sizes relative to the same uncoated catheter. This contrasts with other industry leading coatings that can generate nearly twice as many particles as the same uncoated catheter. Covalon’s Centaur™ coating technology specifically targets and is ideally suited for a growing segment of the medical coatings market focused on improving lubricity while maintaining coating durability.

Saying third party implies there was a second party. Who's devices did they coat? Was this done as simple demonstration, or more in-depth validation?

This part of the business has been forgotten, but a licensing agreement with the right partner for a major market product could be transformative to the company.....